Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

In July 2025 alone, Wegovy clocked Rs 7 crore in sales with around 5,000 injections, while Mounjaro posted Rs 47 crore in ...

Mounjaro manufacturer Eli Lilly has unveiled the test results of its new oral GLP-1 medication, orforglipron. The obesity pill, which is designed to be taken daily by patients who are severely ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral therapy showed a 13.6% drop in weight.

Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by. Welcome to the Q2 2025 ...

New experimental oral weight loss drug, Orforglipron, helped participants lose up to 14.7% of body weight in a Phase 3 trial, ...

A string of blunders led to the value of Novo Nordisk plummeting last week. Could a new weight-loss pill help it regain its ...